TREATMENT OR TARGET TYPE

  Antiangiogenesis | anti-Apoptosis inhibitors | Antibodies | Antibodies & Biologics without chemo | Antisense (anti-bcl-2) | Arsenic Trioxide | Bexxar | Bendamustine | BMS-247550 | Bryostatin | Chemotherapy | Enzastaurin | Enzyme inhibiting | GvHD | HDAC inhibitors | Immune-based | Liposomal Agents | mTOR | ONTAK | Pixantrone | Radiotherapy | Radioimmunotherapy | Revlimid (Lenalidomide) | SAHA |  SGN-30 Stem Cell transplants | Targeted Agents | Vaccines | Velcade - proteasome inhibitor | Zevalin | Other 

See also
Pipeline | New Trials | 7 Reasons to Consider Trials: based on clinical circumstance
   NEW Find Trials by Type of Lymphoma & Treatment Status
NEW Find Trials by Agent / Protocol type

 Anti-angiogenesis

Return to top

Antiangiogenesis agents for lymphoma

All studies     The goal is to target the blood supply that feeds tumors.   More agents of this type...

 Antibodies
(monoclonal) 

with or without chemotherapy

Also see Targeted 
agents below

Return to top

 Antibodies (monoclonal) with or without chemotherapy

Targeted agents that bind to receptors on tumor cells.

	Antibodies (monoclonal) with or without chemotherapy studies Targets a specific receptor type on the surface of malignant cells
	HuMax-cd20 studies  TOPIC SEARCH: Mechanisms PubMed  Outcome ASCO | Medscape | PubMed Safety ASCO | PubMed
	Rituxan studies (Rituximab) TOPIC SEARCH: Mechanisms PubMed

Bispecific antibody studies

Targets two receptor types on the malignant cells with one antibody

TOPIC SEARCH: Mechanisms PubMed 

 

Antibodies & Biologics

excluding chemotherapy

Also see Targeted 
agents below

Return to top

Antibodies (monoclonal) excluding chemotherapy

	studies excluding chemo ...  for previously untreated patients
	studies excluding chemo and radioimmunotherapy
	studies excluding chemo, radioimmunotherapy and Rituxan
	studies of next generation CD20 targeting, not Rituxan (edited Oct 2007) NOTE:  Many next-generation anti-cd20 Mabs are emerging.

Biologics 

studies of Cytokines | Biological response modifiers

Antigen-specific antibodies:

	Anti-Tac (for Tac-expressing lymphoma, including T-cell NHL)
	Daclizumab (t-cell lymphomas)
	CD22-targeting
	Rituxan  (CD20 targeting)

ONTAK (Denileukin Diftitox)

Ontak is a fusion protein which adheres to the interleukin-2 receptor on the malignant cell which may cause cell death.

ONTAK studies

TOPIC SEARCH: Mechanisms PubMed 

SGN-30   

" is a monoclonal antibody that targets the CD30 antigen, which is expressed on hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas. Seattle Genetics is conducting ongoing phase II clinical trials of SGN-30 as a single agent in systemic ALCL and cutaneous ALCL." Press release

SGN-30 studies

TOPIC SEARCH: Mechanisms PubMed 
 

Antibodies combined with biologics: 

	studies of IL-2 |  IL-12 | CpG | Anti-cd80 antibody
	studies of Antisense | G-CSF (Neupogen) |
	NEW: studies of GM-CSF (Leukine)  TOPIC SEARCH: GM-CSF mechanisms with Rituxan PubMed

Cytotoxic (chemo) agents 

And not Transplant

Also see Liposomal chemotherapy below.

 Related topics:

Chemotherapy
 

Return to top

Chemotherapy (general)

	Chemotherapy-based studies: All phases | Phase I | Phase II | Phase III   Chemotherapy is a general term for a systemic therapy.  Click here for details on meaning of Phase I, II, III studies.
	Chemotherapy with biologics studies
	High Dose Cytoxan and biologics studies (by request)

Arsenic Trioxide

Arsenic trioxide may induce cell death (apoptosis) and normalization (differentiation) thru novel pathway(s). Approved for leukemia.

• Arsenic trioxide studies

  TOPIC SEARCH: Mechanisms PubMed 
  
   

Bendamustine 

Bendamustine is an alkylating agent with a nitrogen mustard group and a purine-like benzimidazol group.  It has shown activity against refractory lymphomas - lymphomas resistant to treatment.

Related articles BMR effective - ASH 2006  B + R - ASH 2006

Bendamustine studies

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 

BMS-247550

BMS-247550 studies    Epothilone B-Analog. Primarily for relapsed aggressive lymphomas. TOPIC SEARCH: Mechanisms PubMed

Bryostatin 

Possible mechanism of action: "Bryostatin-1 is believed to bind to the regulatory domain of the PKC enzyme suggesting a mechanism of action distinct from other kinase modulators in development." - gpc-ag.com

Bryostatin studies    TOPIC SEARCH: Mechanisms PubMed

Pixantrone

Might have similar activity against aggressive lymphomas as doxorubicin, with less cardio toxicity.  prnews 

 Related Abstracts:  Pixantrone 

Pixantrone studies

Graft vs Host Disease

 Related Abstracts:

Graft vs Host | Novel
 

Return to top

Graft vs Host Disease studies

All studies  studies for acute GvHD  | chronic GvHD     Graft vs. Host Disease (GvHD) -  a frequent complication of allogeneic bone marrow transplant in which the donor's bone marrow cells attacks the patient's organs and tissue. GvHD tends to be more severe in patients receiving mismatched transplants from family member and in patients receiving unrelated donor transplants.  See GvHD for more detail. TIP: After you click the query above, click Results on Map tab to find locations of the studies in your region.

Immunotherapy

Also see Antibodies and Radioimmunotherapy and  Vaccine  

 Related Abstracts:

general

 vaccines
 

Return to top

Immune-based studies

	Immunotherapy without chemo or radiotherapy | phase I for this type
	CTLA4
	EBV-specific lymphocyte therapy
	Peripheral blood lymphocyte therapy
	Immune-modulator therapy without chemotherapy   The goal of this investigative treatment type is to modify the immune system in order to fight lymphoma or enhance other treatments.

Lenalidomide (CC-5013, Revlimid) 
 
Immune modulation (IMiD) 

"Lenalidomide...  may decrease the production of cytokine and growth factors decreasing the growth of the cells or new blood vessels for the cells. ...  it could also improve the function of natural killer T cells, and enhance immunity.

Lenalidomide is currently approved by the FDA for the treatment of multiple myeloma, another type of cancer that affects circulating plasma cells, which produce antibodies. Lenalidomide is currently awaiting FDA approval for CLL and NHL."

Revlimid (Lenalidomide) studies

Mechanisms PubMed 
 

Gallium Nitrate
Ganite

Return to top

Liposomal 
Delivery of Drugs

Related Abstracts:

liposomal doxorubicin 
 
liposomal vincristine 
 
liposomal antisense

Topics:

 Liposomal chemo

Return to top

Liposomal Delivery of Drugs

Liposomal versions of biologics and chemotherapy   Liposomal delivery of treatments may reduce side effects and/or improve efficacy.

Radiotherapy 

 Related Abstracts:

  radiotherapy
 

Return to top

Radiotherapy 

Radiotherapy all stages - Stage I | Stage II | Stage III | Stage IV Excluding chemotherapy

Radioimmuno-
therapy

Zevalin 
(Y 90 Ibritumomab Tiuxetan)
and Bexxar 
(iodine I 131 tositumomab)

 Related Abstracts:

  Radioimmunotherapy
 

Return to top

Radioimmunotherapy (general)

	All lymphoma studies utilizing radioimmunotherapy (RIT)   RIT studies in Canada (by request)
	RIT for untreated lymphoma
	RIT as part of Stem Cell Transplant (bitly)
	RIT-based sequential therapy  Sequential therapy is following one treatment with another in order to improve on the response of the first.  Also called Consolidation therapy.
	Bexxar | Zevalin  (two approved kinds of RIT)   See Comparing Bexxar and Zevalin
	DLBCL and Radioimmunotherapy
	High dose, or maximum tolerated doses of treatment with RIT

Bexxar (approved)

Bexxar (Tositumomab, Iodine I 131)   Radioimmunotherapy for CD20 positive lymphomas. TOPIC SEARCH: Mechanisms PubMed

Also see Radiolabeled Antibodies

Zevalin (approved) (90Y - Ibritumomab tiuxetan)

Zevalin   Radioimmunotherapy for cd20 positive lymphomas

TOPIC SEARCH Zevalin: Mechanisms PubMed 

Also see Radio-labeled Antibodies

TIP: After you click the query above, click
Results on Map tab to find locations of the studies in your region.

Stem Cell Transplants 

 Related  Abstracts:

 General - all

Allogeneic (from donor) 

Non-ablative (mini)

 Autologous (self)
 

Return to top

Stem Cell Transplants for Lymphoma / CLL

All transplant studies Autologous (from self) * Studies exploring alternative mobilization strategies Allogeneic types (from donor) * Mini - nonmyeloablative transplants for NHL  * TIP: After you click the query above, click Results on Map tab to find locations of the studies in your region. Nonmyeloablative therapy is sometimes called a mini transplant, adoptive immunotherapy, or non-ablative transplant.    With this treatment relatively low dose of chemotherapy are used to suppress the patient's immune system enough to prevent rejection of the donor cells and control the lymphoma. The pre-transplant regimen (chemo) must suppress the lymphoma sufficiently to prevent marked progression of the tumor and allow time for the Graft vs. Tumor (GVT) effect to occur -- which relies on the killing action of the donor’s immune cells to eradicate the remaining disease.

  Targeted agents

Also see antibodies above

Also see Pipeline
 

Return to top

Targeted agents

Targeted therapy is a type of medication that blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with rapidly dividing cells. Targeted cancer therapies may be more effective than current treatments and less harmful to normal cells.    The main categories of targeted therapy are small molecules and monoclonal antibodies.  Source: Wikipedia.org

anti-apoptosis inhibitors 

Agents that target pathways in malignant cells that resist apoptosis

anti-apoptosis inhibitors studies:    ABT-263  | APO866 | AT-101 | GMX1777 | GX15-070 | YM155

 
Antisense (anti-bcl-2) (Oblimersen sodium, Genasense)

Antisense therapy inhibits cell production of bcl-2, a protein that is thought to inhibit cell death and increase resistance to cancer therapies.  Thus, the goal of antisense therapy is to sensitize cancer cells to cancer treatments. It may also have activity as a single agent.

Antisense (anti-bcl-2) studies

TOPIC SEARCH: Mechanisms PubMed 

 
Enzyme inhibiting therapies  

Related topics: Enzyme therapy 
Related Abstracts: proteasome inhibitors

Enzyme Inhibiting studies

Velcade  (PS-341/ Bortezomib) proteasome inhibitor Bortezomib for NHL (Velcade / PS-341)     (Recently approved for Multiple Myeloma and Mantle Cell Lymphoma.) The goal of this investigative treatment type is to inhibit the breakdown of proteins in the malignant cells, which produce and require the elimination of more proteins than normal cells. Also see Studies for Enzyme inhibitor Therapies for lymphoma

Histone deacetylase (HDAC) inhibitor  

Related Abstracts: HDAC

	HDAC inhibitors studies   "HDAC inhibitor MS-275, a benzamide derivative, has demonstrated potent and unique cytotoxicity and anticancer activity in vitro (test tube) in human tumor cell lines and, more importantly, in vivo in human tumor xenografts."
	SAHA   (suberoylanilide hydroxamic acid) (Vorinostat)  Vorinostat  studies TOPIC SEARCH: Mechanisms PubMed

Kinase inhibitors 

all kinase inhibitors studies tyrosine kinase inhibitor studies

Enzastaurin  (LY317615), an acyclic bisindolylmaleimide, is an oral inhibitor of the protein kinase Cbeta isozyme.

Enzastaurin studies

 
mTOR inhibitors 

"In many cancers, mTOR is inappropriately “switched on” due to the abnormal activation of one or more of the upstream signaling pathways that regulate mTOR activity. As a result, mTOR’s ability to inhibit protein synthesis and cause growth arrest when nutrients are scarce becomes compromised."  Background from a sponsor: http://www.targetmtor.com 

mTOR inhibitors for all lymphomas

   Vaccines

 Related Abstracts:

general 

Idiotype-specific 
 

Return to top

Vaccines

Vaccines (Therapeutic)  for Lymphoma   for CLL for follicular Lymphoma  Produced by tobacco plant for Mantle Cell Lymphoma The goal of this investigative treatment is to educate the immune system to identify and target proteins found only on tumors.

  Other New Agents

 Related Abstracts:

Paclitaxel 

SB-715992 - ASCO

Also see Pipeline
 

Return to top

Other New agents

	CDDO   "CDDO is a novel synthetic triterpenoid which is a potent multifunctional molecule. It induces apoptosis in vitro in malignant cells through both intrinsic and extrinsic pathways, and it controls cellular differentiation, apoptosis, and growth inhibition by serving as a ligand for the transcription factor peroxisome proliferator activator receptor- gamma (PPAR gamma ). " Related articles
	SB-715992     "The mitotic kinesin KSP plays an exclusive and essential role in assembly and function of the mitotic spindle. KSP represents a novel target for development of therapeutics against cancer. SB-715992 is a unique and selective inhibitor of KSP, that is preferentially overexpressed in malignant cells, functions exclusively in mitosis, and is not expressed in terminally differentiated neurons." - ASCO | Safety reports
	Elsamitrucin
	Paclitaxel